$CREX

Creative Realities | NT 10-K: Others

This article is a placeholder indicating the filing of an NT 10-K form by Creative Realities. The "NT" designation typically signifies a late filing and that the full 10-K document is pending submission. The content provided is minimal, simply stating "Document".

Original reporting
Published May 1, 2026, 8:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 9:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$CREX
Neutral
medium confidence
Mentioned
$CREX
alphai data visualization · based on Moomoo
Decision brief

The 30-second read

$CREXNeutralLow
01

Why it matters

Given the minimal details and low relevance score, the impact on stock price and trading activity is expected to be limited.

02

Market read

The news has low relevance for traders and is unlikely to influence trading decisions significantly.

03

What to watch

The company's overall financial health and recent performance trends could provide additional context not captured here.

Timing: low

Background

Creative Realities has filed an NT 10-K, indicating a late or pending filing, which is often a procedural matter.

Company-level read

Ticker impact

$CREXNeutralMedium confidence
Context

The news pertains to Creative Realities' filing status, which has minimal immediate trading impact.

Expected impact

No significant price movement expected in the short term.

Evidence & confidence

As the filing is pending and the news provides minimal details, the impact on stock price is likely negligible, especially given the low relevance score.

Market effects

Limited; the news does not suggest sector-wide changes.

Minimal; no regional effects anticipated.

Negligible; the event is company-specific with no apparent global implications.

Counterpoint

Some traders might interpret the delayed filing as a potential red flag, possibly indicating underlying issues.

Key entities

  • Creative Realities

    A company involved in digital media and technology solutions.

Related articles

$CREXMed

Creative Realities, Inc. Q2 2026 Earnings Call Summary

Creative Realities, Inc. reported Q2 2026 revenue of $21.5M, up 65% YoY, driven by CDM integration and new legacy installations. It said it has realized about 75% of $10M targeted annualized synergies. Net loss more than doubled. The company raised $12M via equity, expects record Q3 revenue and higher ARR from Jan 2027, and margin recovery in 2027.

$CREXMed

CREATIVE REALITIES, INC. (CREX): Results of Operations and Financial Condition

CREATIVE REALITIES, INC. (CREX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Creative Realities Reports Fiscal 2026 Second Quarter Results Record Second Quarter Revenue and Improved Outlook as Company Continues Transformation LOUISVILLE, KY – August 13, 2026 – Creative Realities, Inc. (“Creative Realities,” “CRI,” or the

$CREXMedAI 8/10

Creative Realities Announces Pricing of $12 Million Public Offering

Creative Realities, Inc. priced an underwritten public offering of 2,528,571 shares at $3.50 per share and pre-funded warrants for up to 900,000 shares at $3.49 per warrant (plus a $0.01 exercise price). Gross proceeds are expected at about $12.0M. A 30-day option allows the underwriter to buy 428,614 additional shares. Net proceeds will fund working capital, corporate uses, debt paydown, and potential acquisitions; closing expected around June 30, 2026.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.